Cryosupernatant

Cryosupernatant is a plasma product that is obtained from the thawing of frozen plasma. It is used in the treatment of certain medical conditions, such as thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).

Preparation

Cryosupernatant is prepared by thawing frozen plasma at 1-6°C. The thawed plasma is then centrifuged to separate the cryoprecipitate, which contains high concentrations of fibrinogen, factor VIII, and von Willebrand factor. The remaining liquid portion is the cryosupernatant.

Uses

Cryosupernatant is used in the treatment of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). It is also used in patients with coagulation disorders who require large volumes of plasma but do not need the high concentrations of fibrinogen and factor VIII found in cryoprecipitate.

Risks

As with any plasma product, there are risks associated with the use of cryosupernatant. These include the potential for transfusion reactions, infection, and volume overload.

See Also

• Frozen Plasma
• Cryoprecipitate
• Thrombotic Thrombocytopenic Purpura
• Hemolytic Uremic Syndrome